psilocybin has been researched along with Anxiety Disorders in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 13 (65.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leger, RF; Unterwald, EM | 1 |
| Connor, M; Kisely, S; Siskind, D; Somogyi, AA | 1 |
| Knudsen, GM | 1 |
| Calder, AE; Hasler, G | 1 |
| Carhart-Harris, RL; Monson, CM; Wagner, AC; Zeifman, RJ | 1 |
| Arnfred, S; Hovmand, OR; Poulsen, ED; Storebø, OJ | 1 |
| Carpenter, E; Hammond, CJ; Mathews, DB; Matthews, SJ; Nguyen, QA; Patten, CA; Sharma, P | 1 |
| Aaronson, ST; Alexander, JL; Baron, DA; Garakani, A; Gross, LS; Pine, JH; Raison, CL; Sumner, CR | 1 |
| Gerlai, R; Syed, OA; Tsang, B | 1 |
| Wsół, A | 1 |
| Breeksema, JJ; Schimmel, N; Schoevers, RA; van den Brink, W; Veraart, JKE | 1 |
| Andersen, KAA; Carhart-Harris, R; Erritzoe, D; Nutt, DJ | 1 |
| Benyamina, A; Hermand, M; Karila, L; Pétillion, A; Romeo, B | 1 |
| Strauss, N | 1 |
| Aixalà, M; Bouso, JC; Dos Santos, RG; Hallak, JEC | 1 |
| Alcázar-Córcoles, MÁ; Bouso, JC; Dos Santos, RG; Hallak, JEC | 1 |
| Andreassen, OA; Kvam, TM; Stewart, LH | 1 |
| Ardissino, M; John, C; Muttoni, S | 1 |
| Young, SN | 1 |
| Hanes, KR | 1 |
16 review(s) available for psilocybin and Anxiety Disorders
| Article | Year |
|---|---|
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Topics: Affect; Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2022 |
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
Topics: Adult; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Developmental Disabilities; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Sustained effects of single doses of classical psychedelics in humans.
Topics: Anxiety Disorders; Brain; Hallucinogens; Humans; Personality; Psilocybin | 2023 |
Towards an understanding of psychedelic-induced neuroplasticity.
Topics: Anxiety; Anxiety Disorders; Hallucinogens; Humans; Neuronal Plasticity; Psilocybin | 2023 |
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Randomized Controlled Trials as Topic | 2023 |
Psilocybin history, action and reaction: A narrative clinical review.
Topics: Affect; Alcoholism; Anxiety Disorders; Hallucinogens; Humans; Psilocybin | 2023 |
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
The zebrafish for preclinical psilocybin research.
Topics: Animals; Anxiety; Anxiety Disorders; Hallucinogens; Psilocybin; Zebrafish | 2023 |
Cardiovascular safety of psychedelic medicine: current status and future directions.
Topics: Anxiety Disorders; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mescaline; Psilocybin | 2023 |
[Psychedelics for existential distress in terminally ill patients].
Topics: Anxiety Disorders; Hallucinogens; Humans; Psilocybin; Quality of Life; Terminally Ill | 2020 |
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
Topics: Alcoholism; Anxiety Disorders; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin | 2021 |
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.
Topics: Anxiety; Anxiety Disorders; Behavior, Addictive; Hallucinogens; Humans; Psilocybin | 2021 |
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Topics: Anxiety Disorders; Banisteriopsis; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Randomized Controlled Trials as Topic; Serotonin Agents; Substance-Related Disorders | 2018 |
Psychedelic drugs in the treatment of anxiety, depression and addiction.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Substance-Related Disorders | 2018 |
Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2019 |
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Topics: Affect; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety Disorders; Attitude; Behavior; Botulinum Toxins; Depressive Disorder; Facial Expression; Hallucinogens; Humans; Ketamine; Placebo Effect; Psilocybin; Treatment Outcome | 2013 |
1 trial(s) available for psilocybin and Anxiety Disorders
| Article | Year |
|---|---|
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Major; Humans; Psilocybin; Treatment Outcome | 2023 |
3 other study(ies) available for psilocybin and Anxiety Disorders
| Article | Year |
|---|---|
Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.
Topics: Anxiety Disorders; Depressive Disorder; Euthanasia; Hallucinogens; Humans; Psilocybin; Randomized Controlled Trials as Topic | 2017 |
Psychedelics and Personality.
Topics: Anxiety Disorders; Banisteriopsis; Clinical Trials as Topic; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mood Disorders; N,N-Dimethyltryptamine; Personality; Plant Preparations; Psilocybin; Receptor, Serotonin, 5-HT2A; Substance-Related Disorders | 2018 |
Serotonin, psilocybin, and body dysmorphic disorder: a case report.
Topics: Adult; Anxiety Disorders; Body Image; Fluoxetine; Humans; Male; Perceptual Distortion; Psilocybin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents | 1996 |